Tag: Diabetes: Type II
FDA Approves Ozempic for Type 2 Diabetes
Novo Nordisk drug also found to help with weight loss
Remission of Type 2 Diabetes Feasible for Primary Care
Implementation of intensive weight management program linked to remission in 46 percent of patients
Adherence to T2DM Treatment Varies Across Medication Classes
Adherence better for sulfonylureas and thiazolidinediones compared with metformin
Fat Intake Influences HbA1c-Lowering Effect in DPP4i Therapy
Saturated fat intake is significantly correlated with change in HbA1c during DPP4i monotherapy
Severe Hypoglycemia a Potent Marker of Cardiovascular Risk
Findings based on long-term follow-up of patients with diabetes
Brain Glucose Responses Diminish With Diabetes, Obesity
During hyperglycemia, glucose increments lower in patients with obesity, T2DM than in lean participants
First-Line Metformin Use for DM Up; Sulfonylurea Use Down
But sulfonylureas still most common drugs initiated as second-line treatment
ER- Breast CA Risk Up for African-Americans With T2DM
ER- type accounts for increased breast cancer risk in African-American women; highest risk in nonobese
Magnesium, T2DM Link Seen in Poor-Carbohydrate-Quality Diet
Higher magnesium intake tied to lower diabetes risk, especially in lower-carbohydrate-quality diets
Retinal Sensitivity Linked to Cognitive Status in T2DM
Retinal sensitivity assessed by microperimetry is correlated with neurodegeneration parameters
